Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • ROOMS:

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, June 2-6.

“We are pleased to present novel preclinical data from our cell therapy targeting KRAS G12V, highlighting the robust stemness properties of our cell product as a key aspect of its comprehensive characterization. These findings establish a solid research foundation and support our ongoing effort to advance the program as a potential paradigm-shifting treatment for solid tumors,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “Along with our collaborators, we will continue to push forward treatments targeting oncogenic driver mutations and look forward to presenting these findings at ASCO in Chicago.”

Poster presentation details are as follows:

“With the THRIVE™ T cell manufacturing platform, we can generate high yields of drug product exhibiting naïve and central memory phenotypes, enhancing the activity of this therapy,” said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. “Our IND-enabling studies have demonstrated potent and specific pharmacological action with a rigorous toxicology profile that support the advancement of the AFNT-211 program to the clinic.”

About Affini-T Therapeutics

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.